Cardiovascular Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin (KMD-3213), a Drug for the Treatment of Voiding Dysfunction

Tatemichi, Satoshi; Kiguchi, Sumiyoshi; Kobayashi, Mamoru; Yamazaki, Yoshinobu; Shibata, Nobuhiko; Uruno, Tsutomu

doi:10.1055/s-0031-1296773

Cited by 5 publications

(7 citation statements)

References 15 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, this study also showed that the dose required to reduce blood pressure by 20% was about eight fold greater with silodosin than tamsulosin, and about four fold greater than prazosin after intravenous injection (Table 3). 23 In another study in dogs, silodosin did not affect blood pressure, heart rate, or electrocardiographic findings at therapeutic doses 24…”

Section: Selectivity For α1a Adrenoceptorsmentioning

confidence: 92%

Silodosin in the treatment of benign prostatic hyperplasia

Rossi¹,

Roumeguère²

2010

DDDT

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for α1A-adrenergic receptors, as compared with both α1B- and α1D -adrenoceptors, exceeding the selectivity of all currently used α1-blockers, and with clinically promising effects.

show abstract

Section: Selectivity For α1a Adrenoceptorsmentioning

confidence: 92%

Silodosin in the treatment of benign prostatic hyperplasia

Rossi¹,

Roumeguère²

2010

DDDT

View full text Add to dashboard Cite

show abstract

“…Silodosin (0.2 mg (kg day) −1 , diluted in saline, orally (Tatemichi et al . ); selective alpha 1A adrenoceptor antagonist (Shibata et al . )) was the commercial formulation available from Recordati (Urorec ® , Porto Salvo, Portugal).…”

Section: Methodsmentioning

confidence: 99%

“…Silodosin (0.2 mg (kg day) À1 , diluted in saline, orally (Tatemichi et al 2006); selective alpha 1A adrenoceptor antagonist (Shibata et al 1995)) was the commercial formulation available from Recordati (Urorec â , Porto Salvo, Portugal). Sodium pentobarbitone (200 mg kg À1 , intraperitoneal, Eutasil) was acquired from CEVA sant e animal, Alg es, Portugal.…”

Section: Chemicalsmentioning

confidence: 99%

Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Tatemichi et al 31 indicated that silodosin did not affect blood pressure, heart rate or electrocardiogram in conscious dogs with voiding dysfunction. A recent RCT 16 suggested that compared with tamsulosin or placebo, silodosin showed no significant differences in the supine systolic blood pressure, diastolic blood pressure and heart rate.…”

Section: Wilt and Colleaguesmentioning

confidence: 99%

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Ding¹,

Du²,

Hou³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) from randomized controlled trials. We searched PubMed (1966-December 2011), Embase (1974-December 2011 and the Cochrane Library Database (2011, Issue 12). The assessed outcome measures were the change from baseline for the International Prostate Symptom Score (IPSS), quality of life (QoL) score, peak urine maximum flow rate (Q max ), QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Q max (mean difference (MD)522.78, P,0.00001; MD520.42, P50.004; MD51.17, P,0.00001,respectively) and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score (IPSS: MD521.14, P50.02; QoL score: MD520.26, P50.02) and inferior to the 0.2 mg tamsulosin group with respect to Q max (MD520.85, P50.01). In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin. Keywords: benign prostatic hyperplasia (BPH); KMD-3213; lower urinary tract symptoms (LUTS); silodosin; tamsulosin; systematic review; meta-analysis INTRODUCTION Histologically, benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate caused by cellular hyperplasia of both glandular and stromal elements.1 However, it is clinically characterised by lower urinary tract symptoms (LUTS) (urinary frequency, urgency, a weak and intermittent stream, the need to strain, a sense of incomplete emptying and nocturia), and can lead to complications, including acute urinary retention.2 The development of human BPH correlates with increasing age, 3 and LUTS are fairly common after the age of 50 years. 4 As is well known, the treatment options include alpha-blockers, five alpha-reductase inhibitors, transurethral resection of the prostate, transurethral microwave thermotherapy and herbal treatments (saw palmetto and b-sitosterol plant extracts). According to the EAU 2011 guidelines, alpha-blockers are currently the preferred first-line therapy for all men with moderate or severe LUTS/BPH.5 Alpha-blockers for BPH include alfuzosin, prazosin, doxazosin, tamsul...

show abstract

Cardiovascular Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin (KMD-3213), a Drug for the Treatment of Voiding Dysfunction

Cited by 5 publications

References 15 publications

Silodosin in the treatment of benign prostatic hyperplasia

Silodosin in the treatment of benign prostatic hyperplasia

Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Contact Info

Product

Resources

About